Roche un­veils long-term da­ta from piv­otal spinal mus­cu­lar at­ro­phy tri­al

Bio­gen and No­var­tis have pre­vi­ous­ly rolled out long-term da­ta with their re­spec­tive spinal mus­cu­lar at­ro­phy ther­a­pies Spin­raza and Zol­gens­ma. Now, Roche is seek­ing to catch up with four-year da­ta for its block­buster ris­diplam, aka Evrys­di.

Pre­sent­ing at the Mus­cu­lar Dy­s­tro­phy As­so­ci­a­tion Clin­i­cal and Sci­en­tif­ic Con­fer­ence, the phar­ma gi­ant’s sub­sidiary Genen­tech un­veiled pos­i­tive da­ta Mon­day in pa­tients ages 2 to 25 from the SUN­FISH piv­otal study that had ei­ther type 2 or type 3 SMA. In short, Genen­tech said that its spinal mus­cu­lar at­ro­phy drug showed con­tin­ued ef­fi­ca­cy in pa­tients four years af­ter start­ing the ther­a­py.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN